These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 709529)
1. Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma. Haagensen DE; Kister SJ; Panick J; Giannola J; Hansen HJ; Wells SA Cancer; 1978 Sep; 42(3 Suppl):1646-52. PubMed ID: 709529 [TBL] [Abstract][Full Text] [Related]
2. The value of serial plasma levels of carcinoembryonic antigen and gross cyst disease fluid protein in patients with breast carcinoma and osseous metastases. Haagensen DE; Barry WF; McCook TA; Giannola J; Ammirata S; Wells SA Ann Surg; 1980 May; 191(5):599-603. PubMed ID: 7369822 [TBL] [Abstract][Full Text] [Related]
3. Androgen stimulation of gross cystic disease fluid protein and carcinoembryonic antigen in patients with metastatic breast carcinoma. Dilley WG; Leight GS; Silva JS; Ammirata S; Haagensen DE; Wells SA J Natl Cancer Inst; 1983 Jan; 70(1):69-74. PubMed ID: 6571924 [TBL] [Abstract][Full Text] [Related]
4. Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma. Dilley WG; Haagensen DE; Leight GS; Ammirata S; Davis SR; Silva JS; Zamcheck N; Lokich JJ; Wells SA Breast Cancer Res Treat; 1986; 8(3):205-15. PubMed ID: 3593986 [TBL] [Abstract][Full Text] [Related]
5. Monitoring of hormonal therapy in patients with metastatic breast carcinoma by plasma marker protein profiles. Haagensen DE; Dilley WG; Cox CE; Giannola JE; Wells SA Surg Forum; 1978; 29():162-4. PubMed ID: 401123 [TBL] [Abstract][Full Text] [Related]
6. Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen. Silva JS; Leight GS; Haagensen DE; Tallos PB; Cox EB; Dilley WG; Wells SA Cancer; 1982 Mar; 49(6):1236-42. PubMed ID: 6174201 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation. Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Drago J; Rohner T; Haagensen D; Glode M; Santner SJ Anticancer Res; 1984; 4(3):141-4. PubMed ID: 6380398 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Haagensen DE; Kister SJ; Vandevoorde JP; Gates JB; Smart EK; Hansen HJ; Wells SA Cancer; 1978 Sep; 42(3 Suppl):1512-9. PubMed ID: 709523 [TBL] [Abstract][Full Text] [Related]
9. Breast gross cystic disease fluid analysis. I. Isolation and radioimmunoassay for a major component protein. Haagensen DE; Mazoujian G; Dilley WG; Pedersen CE; Kister SJ; Wells SA J Natl Cancer Inst; 1979 Feb; 62(2):239-47. PubMed ID: 283260 [TBL] [Abstract][Full Text] [Related]
10. Non-human primate (baboon) anti-gross cystic disease fluid protein-15 antibody infusion in four women with metastatic breast carcinoma. Estabrook A; Kister SJ; Hardy MA; Grossbard L; Oster MW; Davis S; Mazoujian G; Haagensen DE Cancer Immunol Immunother; 1986; 23(2):143-7. PubMed ID: 3490912 [TBL] [Abstract][Full Text] [Related]
11. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Chia SY; Thike AA; Cheok PY; Tan PH Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Yan Z; Gidley J; Horton D; Roberson J; Eltoum IE; Chhieng DC Diagn Cytopathol; 2009 Jul; 37(7):475-8. PubMed ID: 19217055 [TBL] [Abstract][Full Text] [Related]
13. Biologic markers in breast carcinoma. IV. Serum fucose-protein ratio. Comparisons with carcinoembryonic antigen and human chorionic gonadotrophin. Waalkes TP; Gehrke CW; Tormey DC; Woo KB; Kuo KC; Synder J; Hansen H Cancer; 1978 May; 41(5):1871-82. PubMed ID: 647632 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of serial carcinoembryonic antigen (CEA) determinations in monitoring chemotherapy. Young VL; Kashmiri R; Hazen ZR; Meeker WR South Med J; 1976 Oct; 69(10):1274-6. PubMed ID: 982100 [TBL] [Abstract][Full Text] [Related]
15. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Colomer R; Ruibal A; Salvador L Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682 [TBL] [Abstract][Full Text] [Related]
16. Serum tumor markers in metastatic breast cancer and course of disease. Caffier H; Brandau H Cancer Detect Prev; 1983; 6(4-5):451-7. PubMed ID: 6197167 [TBL] [Abstract][Full Text] [Related]
17. Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen. Tormey DC; Waalkes TP; Snyder JJ; Simon RM Cancer; 1977 Jun; 39(6):2397-404. PubMed ID: 872038 [TBL] [Abstract][Full Text] [Related]
18. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. Mughal AW; Hortobagyi GN; Fritsche HA; Buzdar AU; Yap HY; Blumenschein GR JAMA; 1983 Apr; 249(14):1881-6. PubMed ID: 6834584 [TBL] [Abstract][Full Text] [Related]
19. Hepatic clearance and metabolism in the rat of a human breast cancer associated glycoprotein (GCDFP-15). Toth CA; Haagensen DE; Davis S; Zamcheck N; Thomas P Breast Cancer Res Treat; 1988 Oct; 12(2):235-43. PubMed ID: 3242652 [TBL] [Abstract][Full Text] [Related]
20. Serial tests of carcinoembryonic antigen in patients with breast cancer. Lee YT Am J Clin Oncol; 1983 Jun; 6(3):287-93. PubMed ID: 6846246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]